Agenus has published a study in Cancer Discovery detailing the novel mechanism and effectiveness of its antibody, Botensilimab, in treatment-resistant cancers. The study highlights Botensilimab's increased activity across multiple cancers, its Fc-enhanced design for multifunctional immune activation, and its ability to remodel the tumor microenvironment. The antibody shows promise in treating over nine difficult-to-treat cancers, including microsatellite stable colorectal cancer.